Digital PCR in oncohematology

When you are deciding which technology to use for oncohematology testing, a number of factors come into play. Important points to consider include assay sensitivity, target analysis versus large panels, results interpretation, incidental findings and cost-efficiency.

Digital PCR (dPCR) enables fast, highly sensitive and accurate measurement of gene expression, detection of hotspot mutations and clonality assessment. The high sensitivity and precision – and the fact a reference curve is not required – make dPCR a powerful and attractive molecular tool for oncohematology testing¹.

Join our webinar to discover more about the molecular technologies currently being used, the advantages and disadvantages of these and how dPCR can transform testing for leukemias, lymphomas, myelomas and chronic myeloproliferative neoplasms.

In this webinar, we’ll discuss the following topics:

Overview of currently available molecular technologies
Pros and cons of dPCR, qPCR and NGS for molecular analysis
dPCR as a molecular tool in hematological malignancies

Reference:
1. Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool https://www.mdpi.com/2075-4418/12/6/1305

About the speaker

Dr. Marzia Del Re, Assistant Professor, Clinical Pharmacology and Pharmacogenetics Unit

University of Pisa, Italy

Dr. Marzia Del Re’s research program is focused on the diagnosis of adverse drug reactions by pharmacogenetic analysis of germline DNA and monitoring of acquired resistance to targeted therapies using circulating nucleic acids released from tumors in plasma.Dr. Del Re received her Pharm. D. degree in 2009 and became a Specialist in Clinical Biochemistry at the University of Pisa in 2014. She obtained her Master’s degree in Clinical Trials in Oncology, Hematology and Internal Medicine in 2015 at the University of Pisa and subsequently her PhD in Clinical Pathophysiology. In 2011 and 2013, Dr. Del Re received Merit Awards from the American Society of Clinical Oncology for her studies on DPYD variants and adverse drug reactions by fluoropyrimidines. She received the Umberto Veronesi Foundation Fellowship in 2012 for a project on the pharmacogenetics of tamoxifen. In 2014, Dr. Del Re was the recipient of a special award from the Italian Society of Pharmacology for her contribution to research in pharmacogenetics. In 2016, she received a special award from SIF-Farmindustria for Pharmacological Research. Dr. Del Re received an award from the Italian Association of Medical Oncology in 2018 for her research on circulating tumor DNA in lung cancer.